These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29768500)

  • 1. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
    Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
    J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).
    Joglekar-Javadekar M; Van Laere S; Bourne M; Moalwi M; Finetti P; Vermeulen PB; Birnbaum D; Dirix LY; Ueno N; Carter M; Rains J; Ramachandran A; Bertucci F; van Golen KL
    Neoplasia; 2017 Jul; 19(7):564-573. PubMed ID: 28609680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 6. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
    Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
    Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory breast cancer (IBC): clues for targeted therapies.
    Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
    Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
    Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
    PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
    Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
    J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
    Robertson FM; Chu K; Boley KM; Ye Z; Liu H; Wright MC; Moraes R; Zhang X; Green TL; Barsky SH; Heise C; Cristofanilli M
    J Exp Ther Oncol; 2013; 10(3):219-33. PubMed ID: 24416998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
    Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
    Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
    Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
    Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
    Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.
    Crespo B; Illera JC; Silvan G; Lopez-Plaza P; Herrera de la Muela M; de la Puente Yague M; Diaz Del Arco C; de Andrés PJ; Illera MJ; Caceres S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
    Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
    Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.